This is the second webinar in the BioMedical SIG webinar series, “From Research to Development – Paths to Cross the Valley of Death in Life Sciences”, which showcases initiatives available to European KTOs to maturate technologies with potential in TRL and CRL, without the creation of a spin-off.
In this session, speakers Peter Nussbaumer and Gernot Faustmann will present the KHAN/w4i/LDC initiative. This collaborative drug discovery platform facilitates the translation of world-class science into innovative therapies for the benefit of patients. Their mission is to create value through cooperative drug development partnerships with academic innovators in Europe. They focus on first-in-class therapies for attractive markets with a high unmet medical need.
This webinar is organised by the BioMedical SIG and supported by UCB. Join the BioMedical SIG to stay informed.
There was ample opportunity to learn from colleagues through the workshop sessions or more formally through speakers either sharing their years of experience or their state of the art research. Well worth attending.
John Gleeson
University of Limerick, Ireland
ASTP Conference offers great networking and learning opportunities; a chance to share knowledge with colleagues from various areas of expertise.
Bruno Woeran
Merinova OY - TII President, Finland
The experts, the specific content and the informal setting will improve you as a professional.
Brechtje Vreenegoor
Radboud Universteit, Netherlands
ASTP brought the right structure and terminology to my knowledge of technology licensing.
René Widmer
ETH Transfer, Switzerland
This course gives an in-depth understanding on managing contract portfolio, including research contracts, license agreements, and other collaboration agreements.
Ram Siddappa
Erasmus MC, Netherlands
Join our newsletter and get the latest news